AveXis, for example, said it would be using the funds for a clinical trial and future spinal muscular atrophy trials. And it seems investors are more willing to invest in biotech companies, while staying away from others, because of the value they …
AveXis, for example, said it would be using the funds for a clinical trial and future spinal muscular atrophy trials. And it seems investors are more willing to invest in biotech companies, while staying away from others, because of the value they …
By clicking “SUBSCRIBE NOW,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.
